IMPLANET SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0712 EUR | -2.73% |
|
+0.28% | +11.25% |
| 10/04 | Implanet: first-quarter sales up slightly | CF |
| 09/04 | Implanet S.A. Reports Revenue Results for the First Quarter of 2024 | CI |
| Sales 2022 | 8.03M 8.58M 716M | Sales 2023 | 7.45M 7.96M 664M | Capitalization | 2.62M 2.81M 234M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.21M -268M | Net income 2023 | -6M -6.42M -535M | EV / Sales 2022 | 1.41 x |
| Net Debt 2022 | 6.27M 6.7M 559M | Net Debt 2023 | 5.9M 6.31M 526M | EV / Sales 2023 | 1.15 x |
| P/E ratio 2022 |
-0.97
x | P/E ratio 2023 |
-0.37
x | Employees | 41 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.76% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.73% | ||
| 1 week | +0.28% | ||
| Current month | +2.45% | ||
| 1 month | +0.28% | ||
| 3 months | +4.71% | ||
| 6 months | +35.62% | ||
| Current year | +11.25% |
1 week
0.07
0.07
1 month
0.070.08
Current year
0.060.11
1 year
0.040.19
3 years
0.041.05
5 years
0.045.08
10 years
0.04327.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 27/12/27 | |
David Dieumegard
DFI | Director of Finance/CFO | - | 01/15/01 |
Yvanna Peigné
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 31/10/31 | |
| Chief Executive Officer | - | 27/12/27 | |
| Director/Board Member | - | 10/14/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.0712 | -2.73% | 6,510 |
| 25/24/25 | 0.0732 | -0.81% | 62,813 |
| 24/24/24 | 0.0738 | +3.94% | 50,748 |
| 23/24/23 | 0.071 | -2.74% | 76,260 |
| 22/24/22 | 0.073 | +2.82% | 105,831 |
Real-time Euronext Paris, April 26, 2024 at 08:54 pm IST
More quotes
Implanet SA designs, produces, and sells medical implants and devices used in orthopedic surgery. The group's products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, anchors, etc. Net sales break down by activity as follows:
- spine surgery (94.9%);
- knee surgery and arthroscopy (1%).
The balance of net sales (4.1%) concerns the medical equipment distribution activity.
Net sales are distributed geographically as follows: France (47.1%), Europe/Middle East/Africa (14.3%), the United States (18.5%) and other (20.1%).
Calendar
09/07/2024
- Q2 2024 Sales and Revenue Release
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.25% | 9.5M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- ALIMP Stock
